† 檔案資料。亞培糖尿病照護事業部。
‡ FreeStyle LibreLink 應用程式僅相容於特定的行動裝置及作業系統。使用應用程式前，請查閱我們的相容性指南，詳細瞭解裝置的相容性。
∆ 適用條款及細則。此處可檢查您是否符合條件。
‡‡ LibreLinkUp 應用程式僅相容於特定的行動裝置和作業系統。使用應用程式前，請查看 www.librelinkup.com 詳細瞭解裝置的相容性。需註冊 LibreView 才能使用 LibreLinkUp 和 FreeStyle LibreLink。LibreLinkUp 行動應用程式不可做為主要的血糖監測方式：居家使用者依據應用程式提供的資訊判讀醫療狀況或調整治療之前，務必參照主要監測裝置並諮詢醫師。
§§ LibreView 網站僅相容於特定作業系統及瀏覽器，詳細資訊請參見 www.libreview.com。
## 需註冊 LibreView 才能使用 FreeStyle LibreLink。自動上傳需要無線網路或行動網路連線。
^檔案資料，亞培糖尿病照護事業部資料基於 FreeStyle Libre 系統的全球使用人數，相較於個人傳感器葡萄糖監測系統其他領先品牌的使用者人數。
縮寫：HbA1c/A1 = 糖化血色素；BGM = 血糖監測；CGM = 連續葡萄糖監測；HCP = 專業醫護人員；hypo = 低血糖事件；ISF = 組織間液；MDI = 每日多次注射；RCT = 隨機對照試驗；SMBG = 血糖自我監測；TIR = 目標範圍內的時間；T1D = 第一型糖尿病；T2D = 第二型糖尿病。
References:
- Ajjan R, et al. Continuous Glucose Monitoring: A Brief Review for Primary Care Practitioners. Adv Ther 2019;36:579-596. https://doi.org/10.1007/s12325-019-0870-x.
- Alva S, et al. Accuracy of a 14-Day Factory-Calibrated Continuous Glucose Monitoring System With Advanced Algorithm in Pediatric and Adult Population With Diabetes. J Diabetes Sci Technol 2020. https://doi.org/10.1177/1932296820958754.
- Battelino T, et al. Clinical Targets for Continuous Glucose Monitoring Data Interpretation: Recommendations From the International Consensus on Time in Range. Diabetes Care. 2019. https://doi.org/10.2337/dci19-0028.
- Beck RW, et al. Validation of Time in Range as an Outcome Measure for Diabetes Clinical Trials. Diabetes Care 2019;42(3):400–405. https://doi.org/10.2337/dc18-1444.
- Carlson AL, et al. Flash glucose monitoring in type 2 diabetes managed with basal insulin in the USA: a retrospective real-world chart review study and meta-analysis. BMJ Open Diab Res Care. 2022. https://doi.org/10.1136/bmjdrc-2021-002590.
- Cengiz E, and Tamborlane WV. A tale of two compartments: interstitial versus blood glucose monitoring. Diabetes Technol Ther. 2009;11 Suppl 1(Suppl1):S11-S16. doi:10.1089/dia.2009.0002.
- Charleer S, et al. Quality of Life and Glucose Control After 1 Year of Nationwide Reimbursement of Intermittently Scanned Continuous Glucose Monitoring in Adults Living With Type 1 Diabetes (FUTURE): A Prospective Observational Real-World Cohort Study. Diabetes Care 2020;43(2):389-397. https://doi.org/10.2337/dc19-1610.
- Edge J, Acerini C, Campbell F, et al. An alternative sensor-based method for glucose monitoring in children and young people with diabetes. Archives of Disease in Childhood 2017;102:543-549. https://doi.org/10.1136/archdischild-2016-311530.
- Fokkert M, et al. Improved well-being and decreased disease burden after 1-year use of flash glucose monitoring (FLARE-NL4). BMJ Open Diabetes Research and Care 2019;7:e000809. doi: 10.1136/bmjdrc-2019-000809.
- FreeStyle Libre 2 User Manual (TW).
- Garden GL, et al. HbA1c and hypoglycaemia outcomes for people with type 1 diabetes due to the introduction of a single-day structured education programme and flash glucose monitoring. Br J Diabetes 2021;21:84-88. https://doi.org/10.15277/bjd.2021.284
- Lang J, et al. Expanded Real-World Use Reaffirms Strong Correlation between Scanning Frequency of Flash Glucose Monitoring and Glucose Control. Diabetes 1 June 2019; 68 (Supplement_1): 972–P. https://doi.org/10.2337/db19-972-P.
- Seibold AJ, Minimizing Adverse Skin Reactions to Wearable Continuous Glucose Monitoring Sensors in Patients With Diabetes. J Diabetes Sci Technol. 2021 May;15(3):713-714. doi: 10.1177/1932296820984763.
- Unger J, et al. Practical guidance for using the FreeStyle Libre flash continuous glucose monitoring in primary care. Postgrad Med. 2020 May;132(4):305-313. doi: 10.1080/00325481.2020.1744393.
- Vigersky RA, et al. The Relationship of Hemoglobin A1C to Time-in-Range in Patients with Diabetes. Diabetes Technol Ther. 2019 Feb;21(2):81-85. doi: 10.1089/dia.2018.0310.
- Yaron M, et al. Effect of Flash Glucose Monitoring Technology on Glycemic Control and Treatment Satisfaction in Patients With Type 2 Diabetes. Diabetes Care. 2019 Jul;42(7):1178-1184. doi: 10.2337/dc18-0166.
- Haak T, et al. Flash glucose-sensing technology as a replacement for blood glucose monitoring for the management of insulin-treated type 2 diabetes. Diabetes Ther. 2016. doi: 10.1007/s13300-016-0223-6.
